Chicago products liability partner Dave Sudzus and associate Russ Chibe authored an article for Pharmaceutical Executive, “America’s Opioid Crisis: Potential Increased Regulation of Marketing.” They address concerns that opioid manufacturers may face more scrutiny from federal regulators after President Donald Trump’s declaration of an opioid national health emergency and a recent presidential blue ribbon commission report on the opioid crisis.

Although the blue ribbon commission and President Trump’s national health emergency announcement do not expressly set out to target the pharmaceutical industry, Dave and Russ examine “certain recommendations [that] foreshadow the potential for increased regulation of marketing and increased litigation involving manufacturers of opioids.” In particular, federal regulators may focus on the marketing efforts of opioid manufacturers to prevent improper prescription and addiction. Furthermore, they point out that President Trump’s negative statements about the pharmaceutical industry can sway public opinion and pre-trial publicity in litigation proceedings.

Read “America’s Opioid Crisis: Potential Increased Regulation of Marketing.”


Source: Pharmaceutical Executive
Leave Drinker Biddle to Learn More